| Literature DB >> 28427180 |
Chung-Han Hsin1,2, Ying-Erh Chou1,3, Shun-Fa Yang3,4, Shih-Chi Su5, Yi-Ting Chuang4, Shu-Hui Lin4,6, Chiao-Wen Lin7,8.
Abstract
Matrix metalloproteinase-11 (MMP-11) has been observed in most invasive human carcinomas. The current study investigated the association between the clinicopathological characteristics and MMP-11 expression in oral squamous cell carcinoma (OSCC) patients. Immunohistochemistry (IHC) staining was performed to assess MMP-11 expression in 279 patients with OSCC. In addition, the metastatic effects of the MMP-11 overexpression on the OSCC cells were also investigated. We found that MMP-11 expression was present in 118/279 (42.3%) cases and expression of MMP-11 was associated with higher incidence of lymph node metastasis and worse grade of tumor differentiation. Importantly, OSCC patients with strong expression of MMP-11 had a significantly lower survival rate (p=0.010). Furthermore, MMP-11 overexpression in OSCC cells increased in vitro cell migration. Mechanistically, MMP-11 increased the cell motility of OSCC cells through focal adhesion kinase/Src kinase (FAK/Src) pathway. In conclusion, our results revealed that the MMP-11 expression in OSCC samples can predict the progression, especially lymph node metastasis, and the survival of OSCC patients in Taiwan.Entities:
Keywords: FAK/Src pathway; matrix metalloproteinase; metastasis; oral squamous cell carcinoma; survival
Mesh:
Substances:
Year: 2017 PMID: 28427180 PMCID: PMC5464827 DOI: 10.18632/oncotarget.15824
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Distributions of demographical characteristics in 279 patients with oral cancer
| Characteristics | Total (%) |
|---|---|
| Mean ± SD | 55.80 ± 11.15 |
| Male | 264 (94.6%) |
| Female | 15 (5.4%) |
| Buccal mucosa | 109 (39.1 %) |
| Tongue | 93 (33.3 %) |
| Gingiva | 34 (12.2 %) |
| Palate | 16 (5.7 %) |
| Floor of Mouth | 14 (5.0 %) |
| Others | 13 (4.7 %) |
| I | 53 (19.0%) |
| II | 56 (20.1%) |
| III | 35 (12.5%) |
| IV | 135 (48.4%) |
| T1 | 70 (25.1%) |
| T2 | 88 (31.5%) |
| T3 | 23 (8.2%) |
| T4 | 98 (35.1%) |
| N0 | 176 (63.1%) |
| N1 | 36 (12.9%) |
| N2 | 63 (22.6%) |
| N3 | 4 (1.4%) |
| M0 | 276 (98.9%) |
| M1 | 3 (1.1%) |
| Well | 42 (15.1%) |
| moderate, poor | 237 (84.9%) |
Figure 1MMP-11 expression in primary oral cancer
Tissue microarrays of primary oral squamous cell carcinomas (OSCCs) were immunohistochemically analyzed for MMP-11. (A and D) no detectable MMP-11 (0). (B and E) weak expression levels (1+). (C and F) strong expression levels (2+). (A-C) low-power field (100x); (D-F) high-power field (200x).
Patient characteristics regarding MMP-11 expression
| Characteristics | No. of patients (%) | ||
|---|---|---|---|
| MMP-11 (weak) | MMP-11 (strong) | p value | |
| Total number of patients | 161 (57.7) | 118 (42.3) | |
| <55 | 84 (52.2) | 56 (47.5) | 0.436 |
| ≥55 | 77 (47.8) | 62 (52.5) | |
| Male | 155 (96.3) | 109 (92.4) | 0.154 |
| Female | 6 (3.7) | 9 (7.6) | |
| Buccal mucosa | 71 (44.1) | 38 (32.2) | 0.164 |
| Tongue | 52 (32.3) | 41 (34.7) | |
| Gingiva | 18 (11.2) | 16 (13.6) | |
| Others | 20 (12.4) | 23 (19.5) | |
| I+II | 64 (39.8) | 45 (38.1) | 0.785 |
| III+IV | 97 (60.2) | 71 (61.9) | |
| T1+T2 | 88 (54.7) | 70 (59.3) | 0.437 |
| T3+T4 | 73 (45.3) | 48 (40.7) | |
| N0 | 110 (68.3) | 66 (55.9) | 0.034* |
| N1+2+3 | 51 (31.7) | 52 (44.1) | |
| M0 | 159 (98.8) | 117 (99.2) | 0.752 |
| M1 | 2 (1.2) | 1 (0.8) | |
| Well | 32 (19.9) | 10 (8.5) | 0.009* |
| moderate, poor | 129 (80.1) | 108 (91.5) | |
* p value < 0.05 as statistically significant.
Univariate survival analyses of MMP-11 and clinicopathological parameters among patients with OSCC using the Cox proportional hazard regression model
| All cases (N=279) | Hazard ratio (95% CI) | p value |
|---|---|---|
| Age (<55 versus ≥55) | 0.987 (0.615–1.585) | 0.958 |
| Gender (Male versus Female) | 1.504 (0.530–4.268) | 0.443 |
| Clinical stage (stage I + II versus stage III + IV) | 2.929 (1.780–4.818) | < 0.001* |
| T status (T1 + T2 versus T3 + T4) | 2.185 (1.337–3.569) | 0.002* |
| N status (N0 versus N1 + N2 + N3) | 4.136 (2.398–7.133) | < 0.001* |
| Grade (Well versus moderate, poor) | 2.122 (1.088–4.141) | 0.027* |
| MMP-11 (weak versus strong) | 1.902 (1.166–3.100) | 0.010* |
* p value < 0.05 as statistically significant.
Multivariate survival analyses of MMP-11 and clinicopathological parameters among patients with OSCC using the Cox regression model
| All cases (N=279) | Hazard ratio (95% CI) | p value |
|---|---|---|
| Clinical stage (stage I + II versus stage III + IV) | 0.601 (0.202–1.788) | 0.360 |
| T status (T1 + T2 versus T3 + T4) | 2.878 (1.150–7.204) | 0.024* |
| N status (N0 versus N1 + N2 + N3) | 4.655 (1.973–10.984) | < 0.001* |
| Grade (Well versus moderate, poor) | 1.662 (0.813–3.397) | 0.164 |
| MMP-11 (weak versus strong) | 1.726 (1.017–2.930) | 0.043* |
* p value < 0.05 as statistically significant.
Figure 2Kaplan-Meier survival curve showing the relation between MMP-11 expression in primary tumors and survival in 279 oral squamous cell carcinoma (OSCC) patients
The overall survival of OSCC patients with positive MMP-11 staining was significantly lower than that of OSCC patients with negative MMP-11 staining (p<0.05, log-rank test).
Figure 3The relationships between MMP-11 expression and cell migration in TW2.6 OSCC cell lines
(A) The MMP-11 expression of TW2.6 cells transfected with pcDNA3.0-MMP-11 was examined by western blot and RT-PCR. (B-D) Detection of cell migratory abilities by transfection with MMP-11 overexpression vector in TW2.6 cell. Migratory abilities of pcDNA3.0 and pcDNA3.0-MMP-11 cells were evaluated using (B) wound healing assay. The (C) migratory and (D) invasive abilities of pcDNA3.0 and pcDNA3.0-MMP-11 cells were evaluated using Boyden chamber migration and Matrigel invasion assays. Differences are presented as the mean of triplicate experiments compared with control cells. *p < 0.05 compared with control cells.
Figure 4FAK/Src signaling pathway is involved in MMP-11-promoted cell migration
(A) TW2.6 cells transfected with pcDNA3.0 and pcDNA3.0-MMP-11 overexpression vector for 24 h and the total cell lysates were then subjected to western blot to analyze the phosphorylation of (A) FAK and Src (B) Erk 1/2, JNK1/2 and p38 as described in the Materials and Methods section. (C) TW2.6 cells were treated with a FAK inhibitor (FAKI-14; 10μM) for 24h. FAK phosphorylation was examined by western blot and cell migration was examined by Boyden chamber migration. (D) TW2.6 cells were treated with a Src inhibitor (PPI; 10μM) for 24h. Src phosphorylation was examined by western blot and cell migration was examined by Boyden chamber migration. Data are expressed as the mean ± SEM *p < 0.05 compared with control; #p < 0.05 compared with the pcDNA3.0-MMP-11 overexpression vector group. (E-F) The correlations among mRNA levels of MMP-11 and FAK as well as Src in head and neck squamous cell carcinoma from The Cancer Genome Atlas (TCGA) Data Portal. (E) A significant correlation was found between MMP-11 and FAK (Spearman rank correlation coefficient r =0.2935, p<0.0001). (F) A significant correlation was found between MMP-11 and Src (Spearman rank correlation coefficient r =0.1817, p<0.0001).